This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Do Options Traders Know Something About Heron Therapeutics (HRTX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 0.00% and 12.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up
by Zacks Equity Research
Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.
Biotech Stock Roundup: GILD Submits BLA, ALBO Gains on Study Data & More
by Zacks Equity Research
The biotech sector remains in focus with regulatory and other pipeline updates.
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -3.39% and 38.64%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics (HRTX) in Focus: Stock Moves 9% Higher
by Zacks Equity Research
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.
Heron's Pain Management Drug Gets Complete Response Letter
by Zacks Equity Research
Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.
Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 9.52% and 25.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -12.07% and 0.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio
by Zacks Equity Research
The biotech sector was in focus with pipeline updates from a few small biotech companies.
Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Moving Average Crossover Alert: Heron Therapeutics
by Zacks Equity Research
Heron Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Heron Therapeutics, Inc. (HRTX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Heron Therapeutics, Inc. (HRTX).
Heron Therapeutics (HRTX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 30.00% and 25.64%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2%
by Zacks Equity Research
Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 7.35% and 18.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -70.21% and 15.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.